Received Feb 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 423nl | — |
patient got her 2nd dose of Havrix too early; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 11-year-old female patient who received HAV (Havrix 720) (batch number 423nl, expiry date 16-NOV-2025) for prophylaxis. Previously administered products included Havrix 720 (received 1st dose of Havrix vaccine on 16-OCT-2024). On 22-JAN-2025, the patient received the 2nd dose of Havrix 720. On 22-JAN-2025, an unknown time after receiving Havrix 720, the patient experienced drug dose administration interval too short (Verbatim: patient got her 2nd dose of Havrix too early). The outcome of the drug dose administration interval too short was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 23-JAN-2025 The reporter reported that patient got her 2nd dose of Havrix too early, which led to drug dose administration interval too short. 1st dose was administered on 16-OCT-2024. Second dose was administered 22-JAN-2025.